Molecules of the Month

May 2022

A fat-tissue-targeting clinical candidate, a first-in-class Ph. III molecule that inhibits its target by covalently modifying the target’s substrate, and a fourth-generation glucokinase activator are some examples in Drug Hunter’s May 2022 edition of Molecules of the Month. In this month’s slide deck, you’ll find a molecule that had mitigated QTc prolongation over a prior molecule while hERG inhibition stayed constant, why reversible MAGL inhibition is being pursued, and much more, including:

  • Industry context behind the molecules, target, and clinical applications

  • Biological rationale for drugging the targets

  • Mechanisms of action for the drugs

  • Hit-finding and lead optimization strategies and tactics used

  • Highlights from the binding modes and PDB codes where relevant

  • Interesting aspects from the preclinical and clinical pharmacology

  • Relevant patents and company history

Thanks to reviewers Ron Li, Julien Lefranc, Bryan McKibben, and Romyr Dominique for their nominations and commentary this month.

twitterlinkedinemail

MOTY Nominees

Molecule of the Year

Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.